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Abstract Proteasome-catalyzed peptide splicing (PCPS) of cancer-driving antigens could
generate attractive neoepitopes to be targeted by T cell receptor (TCR)-based adoptive T cell
therapy. Based on a spliced peptide prediction algorithm, TCRs were generated against putative
KRASG12V- and RAC2P29L-derived neo-splicetopes with high HLA-A*02:01 binding affinity. TCRs
generated in mice with a diverse human TCR repertoire specifically recognized the respective
target peptides with high efficacy. However, we failed to detect any neo-splicetope-specific T cell
response when testing the in vivo neo-splicetope generation and obtained no experimental
evidence that the putative KRASG12V- and RAC2P29L-derived neo-splicetopes were naturally
processed and presented. Furthermore, only the putative RAC2P29L-derived neo-splicetopes was
generated by in vitro PCPS. The experiments pose severe questions on the notion that available
algorithms or the in vitro PCPS reaction reliably simulate in vivo splicing and argue against the
general applicability of an algorithm-driven ‘reverse immunology’ pipeline for the identification of
cancer-specific neo-splicetopes.
Introduction
Defined anti-tumor CD8+ T cell responses require the proteasome-dependent processing of intracel-
lular proteins and the efficient generation of antigenic peptides presented in the context of HLA
class I molecules at the cell surface for TCR recognition. An important step in defining the protea-
some as HLA class I epitope generation machine was the early observation that purified 20S protea-
somes in combination with synthetic polypeptide substrates encompassing the epitope of interest
reproduced the in vivo generation of these epitopes with high fidelity (Boes et al., 1994;
Guillaume et al., 2012; Kessler et al., 2006; Niedermann et al., 1995; van der Bruggen and Van
den Eynde, 2006). Thus, in vitro antigen processing experiments in combination with specific CD8+
T cells to monitor HLA class I binding and immune recognition are a widely used reliable tool to ver-
ify the generation efficiency of antigenic peptides of viral, bacterial, and human origin.
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Our view on antigen processing was significantly extended by analysis of cancer patient-derived
CD8+ T cells revealing that by proteasome-catalyzed peptide splicing (PCPS) proteasomes can also
fuse excised peptide fragments in a reverse proteolysis reaction, thereby generating new immune
reactive spliced epitopes (splicetopes) with an amino acid sequence that differs from that of the sub-
strate protein (Hanada et al., 2004; Vigneron et al., 2004). The isolation of splicetope-specific
CD8+ T cells from cancer patients and the finding that splicetope-specific CD8+ T cells derived from
tumor-infiltrating lymphocytes (TILs) inhibited the engraftment of human acute myeloid leukemia
cells in SCID mice indicated the potential immune relevance of such tumor antigen-derived splice-
topes (Robbins et al., 1994).
Importantly, for the fibroblast growth factor (FGF)-5 and several splicetopes derived from the
tumor differentiation antigen gp100mel, in vitro proteasome splicing reactions were also found to
mimic the in vivo splicing reactions (Ebstein et al., 2016; Warren et al., 2006), suggesting that in
vitro PCPS reactions may be a useful tool to discover new spliced epitopes generated from tumor
antigens of interest. To be able to identify splicetopes in in vitro PCPS experiments independent of
the availability of patient-derived CD8+ T cells, we developed the prediction algorithms ProteaJ
(Liepe et al., 2010) and the here-described ProtAG. Using these algorithms, we established an inclu-
sion list of potentially immune-relevant spliced peptides theoretically generated from a given anti-
gen, which in combination with the mass spectrometric analysis of the in vitro digest should allow
the identification of new splicetopes. Testing the feasibility of such an algorithm-aided ‘reverse
immunology’ approach, we had isolated CD8+ T cells from Listeria monocytogenes–infected mice
that specifically recognized two phospholipase PlcB-derived splicetopes generated by the protea-
some in vitro and in vivo (Platteel et al., 2017).
Targeting somatic cancer-specific driver mutations derived from neoantigens by TCR-mediated
adoptive T cell transfer (ATT) represents a promising approach for personalized cancer therapy
(Blankenstein et al., 2015). One drawback of this approach is that often neoepitopes may not
exhibit HLA class I binding affinities sufficient to trigger an efficient T cell response or not be gener-
ated efficiently by the proteasome. In fact, even if a suitable neoepitope is generated, its HLA haplo-
type specificity frequently does not match with the patient’s HLA class I allele, consequently
excluding these tumor patients from ATT.
As outlined above, taking advantage of PCPS for the identification of spliced neoepitopes (neo-
splicetopes) may therefore represent an interesting approach to identify suitable TCR targets when
the recurrent somatic mutations in a tumor antigen do not result in the production of a non-spliced
tumor neoepitope either exhibiting a sufficient HLA class I binding affinity or the appropriate HLA
class I haplotype. Furthermore, due to the ligation of two distant generated peptide fragments
PCPS not only possesses the interesting potential to generate high-affinity neo-splicetopes harbor-
ing the respective somatic mutation but also to extend the HLA haplotype diversity of epitopes gen-
erated from a given neoantigen.
In a proof-of-principle ‘reverse immunology’ study, we here identified HLA-A*02:01 restricted
putative neo-splicetopes predicted by spliced peptide prediction algorithm derived from the two
recurrent somatic mutations KRASG12V and RAC2P29L. TCRs specific for the putative neo-splicetopes
were generated in huTCR-a/huTCR-b gene loci transgenic HLA-A*02:01 mice (Li et al., 2010). TCRs
recognized the respective putative neo-splicetope with high efficacy when tested in vitro. However,
we failed to detect a neo-splicetope-specific T cell response when testing the in vivo (in cellulo) gen-
eration of the predicted neo-splicetopes and thus failed to gain evidence that the two KRASG12V and
RAC2P29Lderived neo-splicetopes were also generated in vivo as predicted by algorithm-aided stud-
ies. In addition, only the predicted neo-splicetope for RAC2P29L could be confirmed by in vitro pro-
teasomal digest. The experiments pose severe questions on the applicability of the previously
highlighted pipeline (Mishto et al., 2019) for the identification of immune-relevant neo-splicetopes.
Results
Prediction of KRASG12V-derived neo-splicetope
KRAS is one of the most frequently mutated genes in human cancer with the G12X (X = V, S, D, A,
C) substitution accounting for most of the mutations found in this position. However, none of these
mutations result in the formation of a non-spliced (linear) high-affinity HLA-A*02:01 binding
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neoepitope (IC50 <100 nM). Since KRAS harbors the oncogenic mutation G12V in approximately
30% of pancreatic ductal adeno carcinoma and 20% of the colon and non-small cell lung cancers, we
used the algorithm ProtAG for theoretical prediction of spliced peptides delineated from the
KRASG12V2-35 protein sequence. The algorithm-predicted spliced 9mer peptides were submitted to
netMHCpan 4.0 (Jurtz et al., 2017) to screen for putative neo-splicetopes with predicted HLA-
A*02:01 binding affinity IC50 <100 nM and carrying the mutant V12 amino acid residue. Using this
approach led to the identification of putative nonamer neo-splicetopes (KRASG12V5-8/10-14, KLVV/
GAVGV, IC50 33.4; sp1), (KRAS
G12V
5-9/11-14, KLVVV/AVGV, IC50 37.50; sp2), and (KRAS
G12V
5-10/12-14,
KLVVVG/VGV, IC50 72.90; sp4), of which sp1 and sp2 allowed for TCR generation
(Blankenstein et al., 2019).
Generation of KRASG12Vsplicetope-specific TCRs in a humanized mouse
model
To analyze the immunogenicity of spliced epitopes, we utilized transgenic mice (ABabDII mice) that
harbor the human TCRab gene loci as a source for a diverse human TCR repertoire that is selected
by chimeric HLA-A*02:01 (Li et al., 2010). Upon immunization with the peptides KLVVGAVGV and
KLVVVAVGV (representing sp1 and sp2, respectively), these mice mounted a CD8+ T cell response
detected by in vitro re-stimulation of peripheral blood lymphocytes 7 days after the last immuniza-
tion, whereas mice without immunization did not show reactivity (Figure 1A, Figure 1—figure sup-
plement 1A). Both peptides induced a specific CD8+ T cell response. By sorting IFNg-positive sp1-
and sp2-reactive CD8+ T cells from splenocytes of responder mice using IFNg-capture assay (not
shown), specific TCRs were isolated upon rapid amplification of cDNA end (50RACE)-PCR and clon-
ing of the most abundant rearranged TCR-a and TCR-b genes for each individual mouse. One TCR
directed against sp1 epitope (1376) and two TCRs specific for sp2 epitope (9383B2 and 9383B14)
were isolated. Codon-optimized sequences encoding the a- and b-chains were linked with a P2A
element and inserted into retroviral expression vector pMP71, transduced into human peripheral
blood mononuclear cells (PBMC) (Figure 1B, Figure 1—figure supplement 1B) and tested for speci-
ficity measuring release of IFNg in a co-culture with TAP-deficient T2 cells loaded with titrated
amounts of sp1 (Figure 1C) or sp2 peptides (Figure 1—figure supplement 1C), respectively. All
three TCRs induced robust IFNg release at peptide concentrations of up to 10 10 M, suggesting
high functional avidity for these TCRs. For TCR1376 and TCR9383B2, cross-reactivity to the in silico pre-
dicted linear KRASG12V KLVVVGAVGV peptide was only seen for the highest peptide concentrations
(Figure 1D and not shown, respectively).
KRASG12Vsplicetope-specific TCRs do not recognize cancer cells
endogenously expressing mutant KRASG12V
One of the critical tests for the usefulness of therapeutic TCRs in genetically modified T cells is the
recognition of cancer cells that endogenously express the respective mutation. This approach was
even more decisive for our approach because so far the predicted neo-splicetopes had been pre-
dicted in silico but not detected in cells. Therefore, PBMC genetically engineered to express sp1-
and sp2-specific TCRs were co-cultured with a series of cancer cell lines that harbored the G12V
mutation within the KRAS gene. MCF7 and Mel624 cells with two KRAS wildtype copies served as
controls. Whereas some of the cell lines used expressed HLA-A*02:01 (Figure 2A, Figure 2—figure
supplement 1A, B), the HLA-A*02:01-negative cell lines were transduced with an HLA-A*02:01
expressing retroviral construct (Figure 2B). Presence of sufficient amounts of HLA-A*02:01 for T cell
recognition was analyzed by prior loading of the tumor cells with 10 6 M of the respective peptide.
In all cases, peptide-loaded cancer cells were recognized by TCR1376 (Figure 2A, B, red bars) or
TCR9383B2 (Figure 2—figure supplement 1A, B, red bars) and TCR9383B14 (Figure 2—figure supple-
ment 1A, B, orange bars) transduced T cells, respectively. In contrast, IFNg release by TCR1376
(Figure 2A, B) or TCR9383B2 and TCR9383B14 engineered T cells (Figure 2—figure supplement
1A, B) was not above background when cancer cells were co-cultured without prior peptide loading,
indicating that the endogenous KRASG12V protein is not recognized. Cancer cells were also treated
with IFNg 48 hr prior to co-culture with the respective TCR-modified PBMCs. As exemplarily shown
for sp2-specific TCRs, again only peptide-loaded tumor cells were recognized (Figure 2—figure sup-
plement 1B).
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Figure 1. Generation and characterization of TCRs specific for spliced epitope 1 (sp1) of mutant KRASG12V. (A) A representative example of ex vivo
intracellular cytokine staining (ICS) analysis of KRAS mutant peptide immunized ABabDII mice (Li et al., 2010) 7 days after the last immunization with
sp1 (KLVVGAVGV). Stimulation with CD3/CD28 beads served as positive control, co-culture without peptide (Ø) was used as negative control. Numbers
in brackets represent percent IFNg+ CD8+ T cells, respectively. Spleens of mice with IFNg-reactive CD8+ T cells were cultured for 10 days in the
presence of 10 8 M of sp1 KRAS peptide, and reactive CD8+ T cells were purified by IFNg-capture assay for isolation of TCR a and b chains by RACE-
PCR. (B) The corresponding TCR a and b chains isolated from one KRASG12V sp1 peptide immunized ABabDII mouse, respectively (1376), were cloned
into retroviral vector pMP71 and reexpressed in human PBMC. Transduction efficacy was measured by staining of the mouse TCRb constant chain on
CD8+ T cells, and the number of positive CD8+ T cells is shown in brackets. (C) TCR gene transfer confers specificity for mutant spliced KRASG12V
peptide KLVVGAVGV (sp1). IFNg production of KRASG12V splice-specific 1376 TCR-transduced T cells upon co-culture with sp1-peptide-loaded T2 cells
Figure 1 continued on next page
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Figure 1 continued
(1376 [solid bars]). As negative control, T2 cells were not peptide loaded. For maximal stimulation, phorbol myristate acetate (PMA) and ionomycin
(p + I) were added to the co-culture. All target cells were also co-cultured with non-transduced T cells (Ø, open bars). (D) TCR gene transfer confers
cross-reactivity for mutant linear KRASG12V peptide KLVVVGAVGV. IFNg production of KRASG12V splice-specific 1376 TCR-transduced T cells upon co-
culture with KRASG12V linear peptide-loaded T2 cells (1376 [solid bars]). As negative control, T2 cells were not peptide loaded. For maximal stimulation,
PMA and ionomycin (p + I) were added to the co-culture. All target cells were also co-cultured with non-transduced T cells (Ø, open bars). Experiments
were done at least in duplicate.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Generation and characterization of TCRs specific for spliced epitope 2 (sp2) of mutant KRASG12V.
Figure 2. The spliced KRASG12V epitope one is not recognized by spliced epitope 1 (sp1)-TCR-redirected T cells. (A) For analysis of natural processing
and recognition of KRASG12V epitopes, cell lines naturally expressing HLA-A2:01 and harboring the KRASG12V mutation and HLA-A2:01+ KRASwt cell line
MCF7 were co-cultured with KRASG12V TCR1376-redirected T cells. (B) HLA-A2:01-negative cell lines were transiently transduced with an HLA-A02:01
expressing retroviral construct (td) and co-cultured as in (A). IFNg production of transduced T cells is shown (red bars). As positive control, peptide-
loaded cells (+) were used, respectively. For maximal stimulation, phorbol myristate acetate (PMA) and ionomycin (PMA/Iono) were added, and all
target cells were also co-cultured with non-transduced T cells (gray bars; Ø); en: endogenous expression of HLA-A2:01. Representative measurements
are shown, and experiments were done at least in duplicate.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. The spliced KRASG12V epitope 1 (sp1) is not recognized by sp2-TCR-redirected T cells.
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T cells harboring KRASG12Vsplicetope-specific TCRs do not recognize
overexpressed KRASG12V
One challenge of targeting neoepitopes with T cells is the low abundance of many neoantigens on
the surface of the respective HLA class I molecules that may hamper recognition by T cells. To
exclude low expression level as one reason for the failure of TCR1376-engineered T cells to recognize
the spliced form of the KRASG12V peptide on the cancer cells, we generated cancer cells (MCF7,
Mel624, and mouse NIH-HHD) that ectopically overexpressed triple minigenes encoding three cop-
ies of the KRASG12V mutation interconnected by an AAY sequence that ensures proteasomal cleav-
age (Spiotto et al., 2002). We therefore generated triple minigene cassettes that either encoded
the N-terminal 35mer polypeptide of KRASG12V1-35 or as control triple minigenes that encoded the
predicted non-spliced 10mer KRASG12V5-14 peptide epitope, the spliced 9mer KRAS
G12V
5-8/10-14, or
KRASwt5-8/10-14 peptide epitope, respectively (Figure 3A). As shown in Figure 3B–D, TCR1376-posi-
tive T cells efficiently recognized the KRASG12V5-8/10-14 peptide when loaded either onto MCF7
(Figure 3B), Mel624 (Figure 3C), and mouse NIH-HHD (Figure 3D) cells or when expressed as a tri-
ple epitope. In contrast, no IFNg release was elicited with cells expressing the triple KRASG12V1-35
35mer polypeptide (Figure 3B–D). Quantitative PCR analysis of KRASG12V triple minigene 35mer
and KRASG12V triple epitope spliced nonamer revealed that KRASG12V triple minigene 35mer is
expressed almost twice as high as the KRASG12V triple epitope spliced nonamer (Figure 3E). Alto-
gether, this indicates that the spliced peptide, theoretically predicted, is either not generated in vivo
or, despite the overexpression of the KRASG12V1-35 substrate, is produced at amounts insufficient to
be recognized by KRASG12V5-8/10-14-specific high-affinity T cells.
KRASG12V splice peptide-specific TCR1376 cross-reacts with HLA-C07
allele
We initially identified two cell lines with the G12V mutation (SW480 and SW620) that induced IFNg
release by TCR1376-transduced PBMC upon co-culture (Figure 3—figure supplement 1A). Upon co-
culture with a panel of lymphoblastoid B cell lines (BLCLs) that harbor a series of different HLA class
I molecules, a test for potential HLA allo-reactivity that we routinely perform with TCRs obtained
from ABabDII mice, we uncovered reactivity to several BLCLs (Figure 3—figure supplement 1B), all
of them having in common the expression of HLA-C*07 (Supplementary file 1). Reanalysis of the
tumor cell lines SW480 and SW620, which originated from the same patient, confirmed expression
of HLA-C*07 molecule (Supplementary file 1). To finally prove HLA allo-reactivity of the TCR1376 to
HLA-C*07, we performed co-culture with the HLA-deficient myelogenous leukemia cell line K562
that had been transduced with HLA-C*07:01, HLA-C*07:02, and HLA-A*02:01 molecules, respec-
tively. The experiments showed that K562-C*07:01 and K562-C*07:02 cell lines were recognized by
three independent TCR1376-transduced PBMC donors irrespective of loading with peptide sp1,
whereas K562-A02:01 cells only induced IFNg release when these cells were loaded with sp1 peptide
prior to co-culture (Figure 3—figure supplement 1C). These results clearly indicate that the TCR1376
directly recognizes members of the HLA-C*07 sub-family and/or peptides bound therein as well as
sp1 peptide bound to HLA-A*02:01.
Triple 35mer polypeptide of KRASG12V1-35 minigenes are not
immunogenic in vivo
In order to analyze whether triple 35mer polypeptide of KRASG12V1-35 minigenes would induce a
CD8+ T cell response in vivo, we performed immunizations of ABabDII mice with an adenovirus
expressing the N-terminal 35mer polypeptide of KRASG12V1-35 as a triple minigene. Despite multiple
immunizations, neither restimulation with the linear 10mer KLVVVGAVGV nor with the spliced epito-
pes sp1 KLVVGAVGV, sp2 KLVVVAVGV, sp3 YLVVVGAVGV, or sp4 KLVVVGVGV induced IFNg
release by CD8+ T cells in an intracellular cytokine staining of PBMCs 7 days after the last immuniza-
tion (Figure 3—figure supplement 2). This supports the notion that the KRASG12V mutation is not
immunogenic in the context of HLA-A*02:01, irrespective of whether splicing events occur or not.
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Figure 3. Co-culture of KRASG12V splice-specific TCR (TCR1376) with human and mouse cells expressing KRAS
G12V
cDNA or triple epitopes. (A) Schematic representation of KRASG12V/wt triple epitopes used for recombinant
overexpression in MCF7, 624Mel, and NIH-HHD cells. TCR1376 was retrovirally transduced into human PBMCs or
TCR1xCD45.1xRag1-/- mouse splenocytes, respectively, and 104 transduced cells were co-cultured 1:1 with target
Figure 3 continued on next page
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Predicted KRASG12V spliced peptides are not generated in in vitro
PCPS reactions
Our failure to detect immune-reactive KRASG12V-derived neo-splicetopes under in vivo conditions
raised doubts with respect to the reliability of the previously proposed solely algorithm-based pipe-
line for identification of immune-relevant neo-splicetopes (Mishto et al., 2019). Therefore, we stud-
ied the generation of the KRASG12V-derived neo-splicetopes in more detail in in vitro PCPS assays.







14 were synthesized. However, due to the extreme hydrophobicity of the KRAS protein, the designed
longer polypeptide substrates KRASG12V2-35 and KRAS
G12V
2-32 encountered considerable difficulties
during synthesis and subsequent purification, resulting in a highly impure product not suited for in
vitro digestion experiments (Figure 3—figure supplement 3). Consequently, we used the polypepti-
des KRASG12V2-21 and KRAS
G12V
2-14 for the in vitro PCPS reactions. KRAS
G12V
2-14 was chosen based
on previous data showing that C-terminal cleavage generating the C-terminal anchor residue is not
essentially required to generate a spliced gp100-derived epitope (Liepe et al., 2010;
Vigneron et al., 2004). Monitoring the kinetics of proteasomal spliced peptide generation repre-
sents an essential parameter for assessing the fidelity of in vitro PCPS reactions. To search for
spliced peptides, a fasta data file generated with ProtAG was loaded onto PD2.1 and the kinetics
analyzed with LC Quan 2.7 (Willimsky et al., 2021). At t = 0, none of the predicted spliced neo-spli-
cetopes was identified. However, following the generation of the KRASG12V-derived putative spliced
neoepitopes from the polypeptide substrates KRASG12V2-14 and KRAS
G12V
2-21 over time in in vitro
PCPS reactions (Figure 3—figure supplements 4 and 5), all three predicted 9mer KRASG12V spliced




5-10/12-14, sp4) were found to be
generated from the KRASG12V2-14 substrate (Figure 3—figure supplement 4). This corroborated
previous findings of Mishto et al., 2019, who reported the in vitro generation of KRASG12V5-8/10-14
and KRASG12V5-9/11-14 from a longer KRAS
G12V
2-35 polypeptide substrate. Using the longer
KRASG12V2-21 polypeptide substrate for the in vitro PCPS reactions, only the putative neo-splicetopes
KRASG12V5-8/10-14 and KRAS
G12V
5-10/12-14 were generated (Figure 3—figure supplement 5A). The
apparent contradiction between our in vivo experiments reported above and the results of the in
vitro PCPS reactions was unexpected, considering that for the several spliced epitopes published so
far there seemed to be a good correlation between the in vitro and in vivo results (Dalet et al.,
2011; Ebstein et al., 2016; Michaux et al., 2014; Mishto et al., 2012; Platteel et al., 2017).
This led us to perform a more detailed MS analysis of the polypeptide substrate used for the in
vitro PCPS experiments. Indeed, we found that most likely the accumulation of hydrophobic amino
Figure 3 continued
cells (B: MCF7; C: 624Mel; D: NIH-HHD). Target cells were loaded with 10 6 M spliced peptide or transduced with
either KRASG12V triple minigene 35mer or KRASG12V triple epitope spliced nonamer. KRASwt triple epitope spliced
nonamer and KRASG12V triple epitope linear decamer were used as control. IFNg production of transduced T cells
is shown (red bars). For maximal stimulation, phorbol myristate acetate (PMA) and ionomycin (PMA/Iono) were
added, and all target cells were also co-cultured with non-transduced T cells (gray bars; Ø). Representative
measurements are shown, and experiments were done at least in duplicate. (E) Relative amounts of KRASG12V
triple minigene 35mer and KRASG12V triple epitope spliced nonamer were determined by qPCR on transduced
NIH-HHD cells. KRASG12V triple epitope spliced nonamer expression is arbitrarily set to 1.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Co-culture of KRASG12V splice peptide-specific TCR (TCR1376) cross-reacts with HLA-C07
allele.
Figure supplement 2. Triple KRASG12V1-35 minigene immunization does not generate cytotoxic T lymphocyte
(CTL) response against predicted linear or spliced HLA-A02:01 epitopes.
Figure supplement 3. Base peak chromatogram of the synthetic polypeptides (A) KRASG12V2-35 and (B)
KRASG12V2-32.
Figure supplement 4. Generation of the predicted putative KRASG12V-derived nonamer neo-splicetopes sp1, sp2,
and sp4 from the synthetic polypeptide substrate KRASG12V2-14 in a kinetic proteasome-catalyzed peptide splicing
experiment.
Figure supplement 5. Generation of the predicted putative KRASG12V-derived nonamer neo-splicetopes sp1 and
sp4 from the synthetic polypeptide substrate KRASG12V2-21 in a kinetic proteasome-catalyzed peptide splicing
experiment.
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acid residues within the KRASG12V polypeptide substrates had led to mistakes during polypeptide
synthesis, resulting in the synthesis of faulty polypeptides (Supplementary file 2) mimicking in
sequence the results of the predicted splicing reaction (Figure 3—figure supplement 5B,
Willimsky et al., 2021). Therefore, it was impossible to decide whether the candidate KRASG12V-
derived spliced peptides identified in vitro were true splicing products or as it appeared the product
of normal proteasomal cleavage of already preexisting faulty polypeptides inappropriately simulat-
ing a splicing event. Furthermore, depending on the substrate, in vitro generation of non-spliced
epitopes can be by orders more efficient than the generation of spliced epitopes (Mishto et al.,
2019). Thus, polypeptide substrates with mistakes in their sequence that are degraded at a rate sim-
ilar to the rate of the correct substrate (Figure 3—figure supplement 5C) may become a prevalent
source for the generation of faked spliced peptides. We eventually obtained a KRASG12V1-21 poly-
peptide substrate (JPT Peptide Technologies, Berlin, Germany) without contaminants mimicking the
predicted KRASG12V5-8/10-14 (sp1) and KRAS
G12V
5-10/12-14 (sp4) splicing events. However, using this
new KRASG12V1-21 polypeptide as substrate for kinetic in vitro PCPS experiments, we now failed to
identify generation of either predicted KRASG12V 9mer neo-splicetope. Although our experiments
cannot completely exclude the generation of minor amounts of KRASG12V-derived spliced peptides,
they are in line with our failure to detect any immune-reactive KRASG12V-derived spliced epitopes in
vivo.
Identification and functional characterization of RAC2P29L-derived neo-
splicetopes
RAC2 is a small GTPase belonging to the Rho family of GTPases. The RAC2P29L mutation is another
so-called driver mutation facilitating tumor growth as well as metastasis and thus presents a poten-
tial target in ATT. The linear RAC2P29L FLGEYIPTV epitope has been predicted with an IC50 of 2 nM.
To identify RAC2P29L-specific neo-splicetopes, we applied the ProtAG algorithm to predict all theo-
retically possible RAC2P29L20-44-derived spliced peptides. From this initial screen, we selected all the-
oretical linear spliced 9mer peptides with a calculated HLA-A*02:01 binding affinity of IC50 < 100
nM (Jurtz et al., 2017). To establish a cleavage map and identify all linear proteasomal cleavage
products generated from the RAC2P29L20-44 polypeptide substrate, we performed in vitro digestions
for 24 hr and 48 hr using erythrocyte and LcL 20S proteasomes (Willimsky et al., 2021). In these
digests, also the non-spliced RAC2P29L28-36 neoepitope FLGEYIPTV was identified (Figure 4A). To
search for spliced peptides, a fasta data file generated with ProtAG was loaded onto PD2.1
(Willimsky et al., 2021). In this search, the spliced RAC2P29L28-34/36-37 (28FLGEYIP34/36VF37) peptide,
with a calculated HLA-A*02:01 binding affinity of IC50 = 24,7 nM, was found to be the only HLA-
A*02:01 restricted putative RAC2P29L neo-splicetope with an IC50 < 100 nM generated. To confirm
the initial identification of RAC2P29L28-34/36-37 kinetic in vitro, PCPS reactions were performed and
analyzed by applying the LC Quan software version 2.5 (Thermo Fisher) (Figure 4B, Figure 4—fig-
ure supplement 1).
The amounts of peptides generated in an in vitro processing reaction can vary dramatically
depending on the assay conditions allowing only a relative estimation. However, judging by ion
counts in vitro generation of the non-spliced RAC2P29L28-36 neoepitope was approximately 200-fold
more efficient than generation of the putative neo-splicetope RAC2P29L28-34/36-37 (Figure 4A).
To exclude that generation of RAC2P29L28-34/36-37 was the result of an accidental singular splicing
event we screened the digests for additional PCPS products. Interestingly, the putative RAC2P29L28-
34/36-37 neo-splicetope seemed to be the result of the excision of a single aa residue (T35) and the
C-terminal ligation of the dipeptide 36VF37 to the N-terminal 28FLGEYIP34 fragment. However, repet-
itive specific ligation of a dipeptide in a PCPS reaction would require the unlikely existence of a cor-
responding specific dipeptide binding site close to the active site and the respective acceptor
fragment.
Therefore, we hypothesized that generation of the RAC2P29L28-34/36-37 spliced peptide was the
result of a multistep process involving a larger already spliced precursor product. Indeed, as shown
in Figure 4B in in vitro kinetic experiments and by detailed mass spectrometric analyses, we identi-
fied the RAC2P29L28-34/36-40 FLGEYIP/VFDNY polypeptide being the largest already spliced epitope
precursor peptide. Supporting that RAC2P29L28-34/36-37 was generated via precursor peptides, we
also detected the corresponding N-terminal splice acceptor peptide RAC2P29L28-34 (FLGEYIP) and
the C-terminal splice donor peptide RAC2P29L36-40 (VFDNY) (Figure 4C). This suggests that
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Figure 4. Non-spliced and spliced peptides generated from RAC2P29L20–44 in kinetic proteasome-catalyzed peptide splicing reactions. The candidate
RAC2P29L neo-splicetope is generated via a C-terminally extended precursor peptide. (A) Kinetics of the generation of the 9mer candidate RAC2P29L28-
34/36-37 neo-splicetope and the non-spliced RAC2
P29L
28-36 neoepitope. Note that generation of the non-spliced RAC2
P29L
28-36 peptide is significantly
more efficient than the generation of the spliced RAC2P29L28-34/36-37. (B) MS/MS spectra of the candidate RAC2
P29L
28-34/36-37 neo-splicetope. (C) Kinetics
Figure 4 continued on next page
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generation of the final RAC2P29L28-34/36-37 neo-splicetope requires an additional C-terminal proteaso-
mal cleavage step for spliced epitope liberation (Figure 4A).
RAC2P29L28-34/36-37 splicetope-specific TCR does not recognize RAC2
P29L
triple epitope 45mer
Spliced RAC2P29L28-34/36-37 peptide-specific TCRs were generated by immunizing ABabDII mice with
the corresponding synthetic 9mer peptides (not shown). For analysis of in vivo generation and pre-
sentation of the spliced RAC2P29L28-34/36-37 peptide, we transduced Mel21a cells to express a triple
RAC2P29L1-45 45mer polypeptide minigene (Figure 5A) and monitored HLA-A*02:01 epitope presen-
tation by T cell recognition. As shown in Figure 5B, no IFNg release was obtained for the putative
neo-splicetope RAC2P29L28-34/36-37 using TCR20967A2-transduced T cells, while peptide-loaded
Mel21a cells were readily recognized and IFNg production demonstrated the target specificity of the
TCR. Thus, despite the overexpression of the RAC2P29L1-45 45mer substrate peptide, we failed to
verify the in vivo generation of the RAC2P29L28-34/36-37 peptide. We also raised a TCR (TCR22894) in
ABabDII mice against the linear RAC2P29L peptide. Because Mel21a cells, transduced to express a
triple RAC2P29L1-45 45mer (Figure 5B) or RAC2
P29L cDNA (Figure 5C), were readily recognized by T
cells transduced with TCR22894, we could exclude that our inability to detect cell surface expression
of the RAC2P29L28-34/36-37 peptide was due to defects in the antigen presentation pathway. We
repeated the experiments with TCR-engineered mouse T cells derived from TCR1xCD45.1xRag1-/-
mouse splenocytes (expressing a monoclonal irrelevant TCR against SV40 large T) to monitor
RAC2P29L28-34/36-37 peptide cell surface expression using mouse NIH-HHD cells expressing a chimeric
HLA-A02:01 (HHD) molecule. As observed in Mel21a cells, the non-spliced RAC2P29L neoepitope
(derived from RAC2P29L1-45 45mer as well as cDNA) was efficiently presented also by NIH-HHD cells,
excluding potential differences in the catalytic properties of mouse and human proteasomes
(Figure 5D). More importantly, again the spliced peptide-specific TCR20967A2 did not confer any
reactivity to T cells upon co-culture without prior peptide loading of the target cells or overexpres-
sion of the spliced epitope (Figure 5B–D). Quantitative PCR analysis of the triple RAC2P29L1-45
45mer polypeptide minigene and RAC2P29L triple epitope spliced nonamer expressed in mouse
NIH-HHD cells revealed that RAC2P29L1-45 45mer polypeptide minigene is expressed almost fivefold
higher than the RAC2P29L triple epitope spliced nonamer (Figure 5E). These experiments do not cat-
egorically exclude any in vivo generation of the in vitro identified RAC2P29L-derived spliced peptide.
However, they clearly demonstrate that even if the RAC2P29L28-34/36-37 neo-splicetope is derived
from an overexpressed substrate protein, its amounts are negligible and insufficient to allow its rec-
ognition by T cells.
In summary, our results strongly question the idea that in vitro PCPS reaction simulates the in vivo
situation with the same high fidelity as the in vitro generation of non-spliced epitopes and contra-
dicts the previously highlighted idea that an algorithm-supported identification of in vitro-generated
spliced epitopes is a suitable general approach for the facilitated identification of tumor-specific
immune-relevant neo-splicetopes for consecutive TCR generation.
Discussion
Effective CD8+ T cell-induced immune responses depend on both the quality and the amount of pro-
teasome-generated antigenic peptides available for presentation by HLA class I molecules to pep-
tide-specific TCR at the cell surface (Niedermann et al., 1999; Princiotta et al., 2003). Not
neglecting TCR affinity or the HLA class I binding affinity of an epitope, in each case the amount of a
Figure 4 continued
of the generation of the non-spliced acceptor FLGEYIP and donor VFDNY peptides and the generation of the C-terminally extended spliced precursor
peptide RAC2P29L 28-34/36-40 FLGEYIP-VFDNY. The MS/MS spectra for the identified RAC2
P29L-derived peptides are shown in Figure 4—figure
supplement 1.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. MS/MS spectra of the identified RAC2P29L-derived peptides.
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Figure 5. Co-culture of RAC2P29L linear-specific TCR (TCR22894) and Rac2
P29L splice-specific TCR (TCR20967A2) with cells expressing Rac2
P29L triple
epitopes and cDNA. (A) Schematic representation of RAC2P29L cDNA and triple epitopes used for recombinant overexpression in Mel21a and NIH-HHD
cells. (B, C) TCRs were retrovirally transduced into human PBMCs and 104 transduced cells were co-cultured 1:1 with Mel21a target cells. (D) TCRs were
retrovirally transduced into TCR1xCD45.1xRag1-/- mouse splenocytes, and 104 transduced cells were co-cultured 1:1 with NIH-HHD target cells.
Figure 5 continued on next page
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specific epitope generated by proteasomes from a given antigen has to rise above a certain thresh-
old to elicit a relevant T cell response.
In addition to substrate amounts and protein turnover rates, epitope generation efficiency of
both non-spliced and spliced epitopes is determined by the sequence of the epitope, its surround-
ing protein sequence, and connected with the cleavage site usage and cleavage strength of protea-
somes (Mishto et al., 2014; Niedermann et al., 1995; Sijts and Kloetzel, 2011). Thus, even high-
affinity peptides, if embedded in a non-favorable protein sequence, will not surpass the necessary
threshold for eliciting a T cell response.
The cleavage properties of proteasomes have been intensively studied. However, due to the
complexity of protein sequences and lacking information on cleavage strength that decisively deter-
mines epitope generation efficiency, algorithms predicting proteasomal generation of immune-rele-
vant non-spliced epitopes still do not reach prediction efficiencies sufficient for large-scale ‘reverse
immunology’ approaches (Calis et al., 2015; Di Carluccio et al., 2018; Singh and Mishra, 2016).
Thus, many predicted epitopes may be false-positives, which could impede immunotherapy,
for example, neoantigen vaccines. Prediction algorithms for spliced epitopes, which are based on
protein sequence and proteasomal cleavage properties, do not even yet exist.
Therefore, in vitro generation of epitopes using purified 20S proteasomes and synthetic polypep-
tide substrates encompassing the epitope(s) of interest, in combination with mass spectrometric
analyses and both in vitro and in vivo CD8+ T cell assays, still represents the most frequently used
tool to validate the generation of immune-relevant non-spliced peptides, assuming that it closely
simulates the in vivo (in cellulo) situation with respect to both quality and relative amounts of the epi-
tope (Kessler et al., 2001; Kessler and Melief, 2007; Sijts and Kloetzel, 2011).
While a number of virus- or tumor-derived non-spliced epitopes have been validated by in vitro
experiments and correlated to the in vivo situation, examples for spliced HLA class I epitopes are still
very limited. Nevertheless, what applied to non-spliced epitopes also seemed to be valid for spliced
HLA class I epitopes generated in vitro by PCPS. Thus, FGF-5, SP110, and several gp100-derived
spliced epitopes that are recognized by CD8+ T cells on the cell surface were demonstrated to be
produced also in in vitro PCPS assays (Ebstein et al., 2016; Vigneron et al., 2019). Although in
these cases the generation efficiency of spliced epitopes in in vitro PCPS assays seemed to be in line
with the in vivo situation, it should be noted, however, that the abundance of spliced epitopes pre-
sented at the cell surface is a matter of substantial controversy (Liepe et al., 2016; Liepe et al.,
2019; Mylonas et al., 2018; Paes et al., 2019; Rolfs et al., 2019). Thus, in light of recent reports
(Mylonas et al., 2018; Rolfs et al., 2019) the amount of cell surface-presented spliced epitope
seems to be considerably less than initially estimated.
On the other hand and supporting a potential immune relevance, the initial discovery of the splic-
ing event and spliced epitopes was based on the identification of patient-derived CD8+ T cells reac-
tive towards spliced epitopes generated from tumor antigens (Hanada et al., 2004; Vigneron et al.,
2004). Widespread identification of spliced epitopes is however limited by the rare availability of
corresponding specific CD8+ T cells. Therefore, we developed prediction algorithms allowing the
mass spectrometric identification of predicted and in vitro proteasome-generated spliced peptides.
Indeed, applying such an algorithm-aided ‘reverse immunology’ approach successfully led previously
to the identification of two spliced phospholipase PlcB epitopes that primed antigen-specific CD8+
T cells in L. monocytogenes-infected mice (Platteel et al., 2017).
Because somatic mutations in tumor antigens frequently do not result in the generation of neoe-
pitopes suitable for generation of TCRs for ATT therapy, we applied spliced peptide prediction algo-
rithms to identify neo-splicetopes with HLA-A*02:01 binding affinity predicted to be generated from
the mutant tumor antigens KRASG12V and RAC2P29L and used those for TCR generation.
Figure 5 continued
Respective human and mouse target cells were loaded with 10 6 M spliced or non-spliced RACP29L peptide, or transduced with either Rac2P29L triple
epitope 45mer, Rac2P29L triple epitope nonamer, or Rac2P29L cDNA. Upon co-culture with recombinant TCR+ T cells, IFNg release was measured. For
maximal stimulation, phorbol myristate acetate (PMA) and ionomycin (PMA/Iono) were added, and all target cells were also co-cultured with non-
transduced T cells (gray bars; Ø). Representative measurements are shown, and experiments were done at least in duplicate. (E) Relative amounts of
Rac2P29L triple epitope 45mer and Rac2P29L triple epitope nonamer were determined by qPCR on transduced NIH-HHD cells. Rac2P29L triple epitope
nonamer expression is arbitrarily set to 1.
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In vitro PCPS experiments in combination with MS analysis aiming at the identification of the
algorithm-predicted putative KRASG12V-derived neo-splicetopes, however, gave no final evidence
for their in vitro generation. In the initial kinetic splicing reactions, we seemed to have identified the
predicted spliced peptides, thereby corroborating also data obtained with a KRASG12V2-35 polypep-
tide substrate reported by Mishto et al., 2019.
However, we found that most likely the extreme hydrophobicity of the KRAS amino acid composi-
tion had led to faulty polypeptide synthesis, resulting in polypeptide substrates mimicking in
sequence the results of the predicted splicing reaction (Figure 3—figure supplement 5,
Supplementary file 2). Considering that in general the generation of spliced peptides is significantly
less efficient than that of non-spliced peptides (Figure 4A), even minor amounts of faulty peptide
substrates will become prevalent in in vitro splicing reactions (see also Figure 3—figure supplement
5B). Because high-quality peptide synthesis reaches a purity of 95–99% at most, a thorough sub-
strate analysis appears essential to avoid false-positive results in in vitro PCPS experiments, particu-
larly for chemically difficult substrates. However, when we used a newly synthesized KRASG12V
substrate not contaminated with peptides mimicking the KRASG12V5-8/9-14 and KRAS
G12V
5-10/12-14
splicing reactions, we failed to identify the in silico-predicted neo-splicetope. This negative result
cannot finally prove the non-existence of the KRASG12V5-8/9-14 and KRAS
G12V
5-10/12-14, but being in
line with the in vivo experiments, one has to conclude that if these KRASG12V-derived spliced epito-
pes are generated, then their amount is below detectable level. In contrast to the negative results
obtained with respect to KRASG12V, the analysis of RAC2P29L led to the identification of the in silico-
predicted RAC2P29L28-34/36-37 peptide in in vitro PCPS experiments. Nevertheless, the putative
RAC2P29L28-34/36-37 neo-splicetope was generated significantly less efficient than the non-spliced
RAC2P29L28-36 neoepitope.
Testing the in vivo generation of the spliced KRASG12V5-8/10-14 and RAC2
P29L
28-34/36-37 peptides
using the respective peptide-specific TCRs, which were of high affinity and recognized as little as
10 10 M peptide, we obtained no T cell signal and no evidence for the immune relevance of the two
candidate neo-splicetopes, independent of the experimental conditions. Our experiments provide
no evidence that either KRASG12V5-8/10-14 or RAC2
P29L
28-34/36-37 are produced in vivo or presented at
the cell surface. However, even in case both neo-splicetopes were generated in vivo, their genera-
tion efficiency and the total amount presented by HLA-A*02:01 molecules on the cell surface are too
low to be of any immune significance. One possible explanation for the failure to verify the in vitro
PCPS reaction for RAC2P29L28-34/36-37 in in vivo settings could be the high substrate and proteasome
concentration as used for in vitro PCPS, thereby forcing splicing reactions that do either not or only
inefficiently occur under in vivo conditions where only a single substrate protein enters the catalytic
cavity of the proteasome for processing at a given time.
Thus, quite in contrast to the experience resulting from proteasome-dependent processing of
non-spliced epitopes in vitro, in vitro generation of spliced epitopes by PCPS may not exhibit the
same fidelity and does not always simulate the efficacy of in vivo spliced epitope generation. This of
course strongly questions the general application of the recently highlighted experimental pipeline
for the identification of cancer-specific neo-splicetopes (Mishto et al., 2019). Reconsidering the
workflow for the identification of neo-splicetopes, it thus seems that in vitro PCPS even when com-
bined with peptide binding and TAP transport assays are not sufficient for the prediction of their
immune relevance. We therefore believe that it is mandatory to first prove the cell surface presenta-
tion of algorithm-predicted candidate neo-splicetopes, either in humanized mice under conditions
requiring processing and presentation or by peptide elution experiments, before TCR generation.
Our data also support the notion (Mylonas et al., 2018) that the frequency of spliced epitopes is
largely overestimated.
Materials and methods
Peptides, proteasome, and PCPS






35(TEYKLVVVGAVGVGKSALTIQLIQNHFVDEYDPT), as well as the RAC2
P29L
20-44 (BIH 5) polypeptide
substrate (LISYTTNAFLGEYIPTVFDNYSANV) were synthesized by the core facility of the Institute of
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Biochemistry (Dr. Petra Henklein) using standard Fmoc (N-(9-fluorenyl) methoxycarbonyl) methodol-
ogy (0.1 mmol) on an Applied Biosystems 433A automated synthesizer. The peptide was purified by
HPLC and analyzed by mass spectrometry (ABI Voyager DE PRO). The KRASG12V1-21 (MDC 27) (MTE
YKLVVVGAVGVGKSALTI) polypeptide substrate was obtained from JPT Peptide Technologies (Ber-
lin, Germany). 20S proteasomes were purified from human red blood cells, LcL or T2.7 cells in princi-
ple following the procedure as previously described (Textoris-Taube et al., 2019). Proteasome
composition of LcL and T2.7 cells, which express immunoproteasomes, however, may vary depen-
dent on batch and culture conditions. For kinetic experiments and better comparison, therefore only
the results obtained with erythrocyte 20S proteasomes were used for the kinetic experiments. Pro-
teasome digests of the synthetic RAC2P29L and KRASG12V polypeptides were performed in 100 ml of
TEAD buffer (20 mM Tris, 1 mM EDTA, 1 mM NaN3, 1 mM DTT, pH 7.2) over time at 37˚C. For
establishing a cleavage map for RAC2P29L20-44, processing times were 24 hr and 48 hr. The
RAC2P29L20-44 and KRAS
G12V
1-21 synthetic polypeptide at a concentration of 60 mM was digested by
8 mg 20S proteasome. Proteasomal processing of the synthetic KRASG12V2-21 and KRAS
G12V
2-14 poly-
peptides was performed at a substrate concentration of 40 mM or 60 mM and in the presence of 4
mg or 8 mg 20S proteasome, respectively. 10 ml digested sample was loaded for 5 min onto a trap




, Thermo Fisher Scientific) with 2:98 (v/v) ace-
tonitrile/water containing 0.1% (v/v) trifluoroacetic acid (TFA) at a flow rate of 20 ml/min and ana-
lyzed by nanoscale LC-MS/MS using an Ultimate 3000 and LTQ Orbitrap XL mass spectrometer
(Thermo Fisher Scientific). The system comprises a 75 mm i.d. 250 mm nano LC column (Acclaim
PepMap C18, 2 mm; 100 Å; Thermo Fisher Scientific) or a 200 mm PicoFrit analytical column (Pep-
Map C18, 3 mm, 100 Å, 75 mm; New Objective). The mobile phase (A) is 0.1% (v/v) formic acid in
water and (B) is 80:20 (v/v) acetonitrile/water containing 0.1% (v/v) formic acid. For elution, a gradi-
ent 3–45% B in 85 min with a flow rate of 300 nl/min was used. Full MS spectra (m/z 300–1800) were
acquired on an Orbitrap instrument at a resolution of 60,000 (FWHM). At first, the most abundant
precursor ion was selected for either data-dependent collision-induced dissociation (CID) fragmenta-
tion with parent list (1+, 2+ charge state included). Fragment ions were detected in an Ion Trap
instrument. Dynamic exclusion was enabled with a repeat count of 2 and 60 s exclusion duration.
Additionally, the theoretically calculated precursor ions of the expected spliced peptides were pre-
elected for two Orbitrap CID (resolution 7500) and higher energy collisional dissociation (HCD) (reso-
lution 15,000) fragmentation scans. The maximum ion accumulation time for MS scans was set to
200 ms and for MS/MS scans to 500 ms. Background ions at m/z 371.1000 and 445.1200 act as lock
mass.
For LC-MS/MS runs using a Q Exactive Plus mass spectrometer coupled with an Ultimate 3000
RSLCnano (Thermo Fisher Scientific), samples were trapped as described above and then analyzed
by the system that comprised a 250 mm nano LC column (Acclaim PepMap C18, 2 mm; 100 Å; 75
mm Thermo Fisher Scientific). A gradient of 3–40% B (alternatively 3–45% B) in 85 min was used for
elution. The mobile phase (A) was 0.1% (v/v) formic acid in water and (B) 80% acetonitrile in water
containing 0.1% (v/v) formic acid. The Q Exactive Plus instrument was operated in the data-depen-
dent mode to automatically switch between full-scan MS and MS/MS acquisition. Full MS spectra
(m/z 200–2000) were acquired at a resolution of 70,000 (FWHM) followed by HCD MS/MS fragmen-
tation of the top 10 precursor ions (resolution 17,500, 1+, 2+, 3+, charge state included, isolation
window of 1.6 m/z, normalized collision energy of 27%). The ion injection time for MS scans was set
to maximum 50 ms, automatic gain control (AGCs) target value of 1  106 ions and for MS/MS scans
to 100 ms, AGCs 5  104, dynamic exclusion was set to 20 s. Background ions at m/z 391.2843 and
445.1200 act as lock mass.
Peptides were identified by PD2.1 software (Thermo Fisher Scientific) based on their merged tan-
dem mass spectra (MS/MS) of CID and HCD. For peptide identification, we set mass tolerances of
either 10 ppm (for XL mass spectrometer) or 6 ppm (for Q Exactive mass spectrometer) on precursor
masses and either 0.6 Da for fragment ions using Ion Trap or 0.06 Da using Orbitrap for fragmenta-
tion (for XL mass spectrometer) or 0.02 Da (for Q Exactive mass spectrometer).
In addition, for spliced peptides we compared the retention time and the merged MS/MS of CID
and HCD with the fragmentation pattern of their synthetic counterparts. To identify spliced pepti-
des, a fasta data file was generated with ProtAG for the KRASG12V and RAC2P29L polypeptide sub-
strates and loaded onto PD2.1. The kinetics were analyzed with LC Quan 2.7. HLA-A*02:01 binding
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affinity of putative spliced epitopes was calculated by the netMHCpan 4.0 algorithm (Jurtz et al.,
2017).
Cell lines
T2 cells (ATCC: CRL-1992) were kept in RPMI supplemented with 10% fetal calf serum (FCS). The
viral producer cell line HEK-GALV (HEK-293 cells stably expressing GALV-env and MLV-gag/pol) was
cultured in DMEM supplemented with 10% FCS. Human peripheral blood mononuclear cells
(hPBMCs) and Epstein–Barr virus–transformed lymphoblastoid B cell lines (B-LCLs; Obenaus et al.,
2015) were cultured in RPMI 1640 supplemented with 10% FCS, 50 mM 2-mercaptoethanol, 1 mM
sodium pyruvate, and non-essential amino acids. The human cell lines with KRASG12V mutation were
obtained from ATTC (AsPC-1 [ATCC: CRL-1682]; Capan-1 [ATCC: HTB-79]; CFPAC-1 [ATCC: CRL-
1918]; NCI-H441 [ATCC: HTB-174]; NCI-H727 [ATCC: CRL-5815]; Panc 03.27 [ATCC: CRL-2549];
SW480 [ATCC: CRL-228]; SW620 [ATCC: CRL-227]) or Sigma-Aldrich (Colo668). The human cell lines
carrying wildtype KRAS gene were MCF-7 (Sigma-Aldrich) and 624-Mel (RRID:CVCL_8054). K562
cells expressing HLA-A02:01, HLA-C07:01, and HLA-C07:02 molecules were obtained after transduc-
tion of K562 cells with retroviral vectors MP71 encoding the respective HLA molecules. The human
melanoma cell line UKRV-Mel-21a (referred to hereafter as Mel21a) and the mouse cell line NIH-
HHD have been described in Sun et al., 2002 and Popovic et al., 2011, respectively. Cancer cell
lines were kept in RPMI (Gibco) supplemented with 10% FCS (Pan Biotech), 1 mM L-glutamine, 1
mM sodium pyruvate, and non-essential amino acids. For HLA-A02:01 negative cell lines AsPC-1,
Capan-1, NCI-H727, and Colo668 HLA-A02:01 expression was achieved by transient transfection
with plasmid pMP71-A2 (retroviral vector encoding HLA-A*0201). All human tumor cell lines were
authenticated by sequencing for the presence of the mutant or wildtype KRASG12V configuration
(Chang et al., 2013), and all experiments were performed with mycoplasma-free cells.
Generation of neo-splicetope-specific T cells in ABabDII mice
For immunization (priming and successive boosts), ABabDII mice were injected subcutaneously with
100 mg of peptide (KLVVVGAVGV [KRASG12V-lin], KLVVGAVGV [KRASG12V-sp1], KLVVVAVGV
[KRASG12V-sp2], YLVVVGAVGV [KRASG12V-sp3], KLVVVGVGV [KRASG12V-sp4], FLGEYIPVF [RAC2P29L
spliced], JPT) in a 200 ml 1:1 solution of incomplete Freund’s adjuvant and PBS supplemented with
50 mg CpG. Repetitive immunizations were performed with the same mixture at least 3 weeks apart.
KRAS/RAC2-specific CD8+ T cells in the peripheral blood of immunized animals were assessed by in
vitro peptide restimulation and subsequent intracellular cytokine staining (IFNg) 7 days after each
boost.
Isolation and cloning of KRASG12V-sp1, KRASG12V-sp2-specific, and
RAC2P29L splice-specific TCRs
Splenocytes and lymphocytes from inguinal lymph nodes were prepared from responding animals at
day 8 after the last boost. For in vitro culture, CD4+ T cells were depleted by CD4 microbeads (Mil-
tenyi Biotech, Bergisch Gladbach, Germany) and 1  106 splenocytes were seeded per well of a 24-
well plate and expanded for 10 days in RPMI 1640 medium supplemented with 10% FBS gold,
HEPES, NEAA, sodium pyruvate, 50 mM b-mercaptoethanol, 20 IU/ml human IL-2, and 10 8 M sp1,
sp2 or RAC2 peptide, respectively. Splenocytes were stimulated with 10 6 M peptide for 4 hr before
mouse IFNg secretion assay (Miltenyi Biotech). The cells were treated with Fc Block, stained with
antibodies against mouse CD3-APC and mouse CD8-PerPC (BD Biosciences, San Jose, CA, USA).
IFNg secreting CD8+ T cells were sorted with BD FACS Aria III (BD Biosciences) into RTL lysis buffer
for RNA isolation with RNeasy Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. First-strand cDNA synthesis and 50-RACE PCR were carried out using SMARTer RACE
cDNA Amplification Kit (Clontech Laboratories) according to the manufacturer’s instructions. In par-
ticular, subsequent TCR-specific amplification was carried out with 1–2 ml of the reverse transcription
reaction, 1 U Phusion HotStart II polymerase (Thermo Scientific), 0.1 mM of either hTRAC (50-
cggccactttcaggaggaggattcggaac-30) or hTRBC (50-ccgtagaactggacttgacagcggaagtgg-30) primers and
0.1 mM 50 primer (50-ctaatacgactcactatagggcaagcagtggtatcaacgcagagt-30). The amplified TCR genes
were analyzed on an agarose gel and specific bands were cut out and cloned using a Zero Blunt
TOPO PCR cloning kit (Life Technologies). Plasmids from individual clones were isolated and
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sequenced using a T3 primer (50–30) at Eurofins Genomics. Dominant TCR-a/b chains were selected
and paired as follows: 1376 TCR (TRAV5*01 – CAESTDSWGKLQF – TRAJ24*02, TRBV4-1*01 –
CASSQDLAGYEQYF – TRBJ2-7*01), 9383B2 TCR (TRAV17*01 – CATDEDTGNQFYF – TRAJ49*01,
TRBV12-3*01 – CASSLWGYEQYF – TRBD1*01 – TRBJ2-7*01), 9383B14 TCR (TRAV17*01 – CAT-
DEDTGNQFYF – TRAJ49*01, TRBV12-3*01 – CASSLVGYEQYF – TRBD1*01 – TRBJ2-7*01), and
20967A2 TCR (TRAV20*02 – CAVQAPDSGNTPLVF – TRAJ29*01, TRBV2*01 – CASSDRGAYNEQFF –
TRBD1*01 – TRBJ2-1*01). The TCR constant regions were replaced with mouse counterparts. Paired
TCR-a/b chains were linked with a P2A element. TCR cassette was codon optimized, synthesized by
GeneArt (Thermo Fisher Scientific, Waltham, MA, USA) and cloned into pMP71 by NotI/EcoRI
restriction site cloning.
TCR gene transfer
TCR gene transfer was carried out as described before (Niedermann et al., 1995). In brief, packag-
ing cell line HEK-293-GALV (amphotropic) or Plat-E (ecotropic) were grown to approximately 80%
confluence and transfected with pMP71 vector carrying the TCR cassette using Lipofectamine2000
(Life Technologies), and retrovirus-containing supernatant was harvested 48 hr and 72 hr after
transfection.
Human PBMCs were isolated from healthy donors by Ficoll gradient centrifugation. 1  106
freshly isolated or frozen hPBMCs were stimulated with 5 mg/ml anti-CD3 (OKT3) and 1 mg/ml anti-
CD28 (CD28.2) (BioLegend)-coated plates in the presence of 300 U/ml recombinant human interleu-
kin 2 (hIL-2, Peprotech). Transductions were performed 48 hr and 72 hr after stimulation by addition
of retrovirus-containing supernatant and 4 mg/ml protamine sulfate followed by spinoculation. Trans-
duced T cells were kept in the presence of 300 U/ml hIL-2 for a total of 2 weeks followed by at least
2 days of culture in the presence of 30 U/ml hIL-2, before they were used for experiments.
For transduction of mouse T cells, spleen cells were isolated from TCR1xCD45.1xRag1-/- mice
(expressing a monoclonal-irrelevant TCR against SV40 large T), erythrocytes were lysed, and cells
were stimulated in medium (RPMI 1640, 10% FCS, 100 IU/ml penicillin-streptomycin, 1 mM sodium
pyruvate, 1 non-essential amino acids, 50 mM 2-mercaptoethanol) supplemented with 1 mg/ml anti-
mouse CD3, 0.1 mg/ml anti-mouse CD28 antibodies (both BD Biosciences (BD), Franklin Lakes, NJ,
USA), and 10 IU/ml human IL-2 (Proleukin S, Novartis, Basel, Switzerland) at a concentration of 2 
106/ml. 1  106 cells were transduced twice by spinoculation in the presence of 10 IU/ml IL-2 and 4
 105 mouse T-Activator beads (Life Technologies). T cells were expanded in medium (+50 ng/ml IL-
15; Miltenyi Biotec) for 10 days before co-culture.
Functional assays
IFNg production was measured by ELISA after 16 hr co-culture of 1  104 TCR-positive T cells with 1
 104 target cells (human/mouse tumor cell lines or peptide-loaded T2 cells). Stimulation with phor-
bol myristate acetate (PMA) and ionomycin was used as a positive control. All samples were mea-
sured in duplicate.
Flow cytometry
The following conjugated antibodies were obtained from BioLegend: anti-hCD3 (HIT3a), anti-hCD8
(HIT8a), anti-hHLA-A2 (BB7.2), anti-hHLA-ABC (W6/32), anti-mCD3 (145-2 C11), anti-mCD8 (53-6.7),
anti-mIFNg (XMG1.2), and anti-mTCR-b (H57-597). Samples were analyzed using MACSQuant (Milte-
nyi) or FACSCalibur (BD Biosciences). Data analysis was performed using FlowJo (Treestar).
Quantitative PCR (qPCR)
RNA was isolated from 1  106 NIH-HHD cells using the NucleoSpin TriPrep (MACHEREY-NAGEL).
After RNA quality and integrity were verified, 2.8 mg of total RNA were used as template for cDNA
synthesis with random hexamers, using SuperScript III Reverse Transcriptase (Invitrogen). Samples
were diluted 1:5 and 5 ml used as template in a 20 ml qPCR reaction using SYBR Green PCR Master
Mix (Thermo), with 500 nM primer concentration. Primer sequences: GFP: F:50-acgacggcaactacaa-
gacc-30, R:50-tgaagtcgatgcccttcag-30; Gapdh: F:50-tggagaaacctgccaagtatg-30, R:50-gttgaagtcgcagga-
gacaac-30. Samples were run on the QuantStudio 3 Real-Time PCR system (Thermo Fisher) and
analyzed according to the comparative DDCt method.
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ProtAG prediction algorithm
The ProtAG prediction algorithm was used in combination with mass spectroscopy to identify pepti-
des and spliced peptides derived from an oligomeric protein substrate. The peaks of the MS inten-
sity profile were approximated by Gaussian functions. Goodness of fit was used as one criterion for
assessing the reliability of a mass peak. Only peaks above a user-defined noise threshold were com-
piled together with their HPLC retention times. The likelihood for correctly assigning a peptide to an
MS peak was scored by the correspondence between computational and experimental values for
peptide mass, occurrence of expected m/z values, similarity of retention times, and tandem MS/MS
data. Chemically modified peptides (e.g., by oxidation) were identified by adding to the theoretical
mass the masses of possible modifiers. Such modified peptides were included into the list of identi-
fied peptides only if the non-modified peptide could also be identified. After assigning the MS peaks
to all direct or chemically modified fragments that theoretically can be derived from the protein sub-
strate by one or multiple cleavages, a group of significant but ‘unexplained’ MS peaks remains,
which may represent possible spliced products, that is, peptides composed of fragments distant in
the parental protein substrate. The likelihood for correctly assigning a splice peptide to unexplained
MS peaks was computed in the same way as for conventional peptides, including the additional cri-
terion, that the two fragments merged together in the presumed splice peptide were also present in
the set of identified conventional peptides.
Proteasomal cleavage products (PCP) of a substrate peptide can clearly be described by the num-
bers of the first and last amino acid within the substrate: P(i,j) denominates the peptide of length
j-i +1 starting with amino acid i and ending with amino acid j. Proteasomal splice products (PSP) con-
sist of two such fragments, therefore denominated by SP(i,j,k,l), consisting of the peptides P(i,j) and
P(k,l) and having a length of (j + l-i-k + 2). They can be in normal order (i < j < k < l), inverse order (k
< l < i < j), or overlapping. Overlapping splice product means that there exists a position m that is
both part of P(i,j) and P(k,l), therefore max(i,j) <= min(j,l), meaning that the splice product consists of
parts of two substrate peptides.
Splice peptides in normal order with j + 1 = k are identical to the original PCP P(i,l) and should
therefore be excluded. Splice peptides can have the same sequence like PCPs, for example, if the
sequence of the substrate is redundant, or the length of one of the parts is short – such peptides
can be excluded from the database. Splice peptides can have the same sequence, so the splice pep-
tides SP(i,j,k,l) and SP(i,j + 1,k + 1,l) have the same sequence if the amino acid in position j + 1 and
in position k are the same. Nevertheless, both versions should be kept within the database because
if the original peptides P(i,j) and P(k,l) are found within the cleavage products, and P(i,j + 1) not, the
first version of the PSP is more likely.
When searching for splice products that are at the same time epitopes for MHC class I or MHC
class II, the length of the predicted splice products should be limited. Therefore, according limits are
included into the algorithm. Also, the database of spliced products can become very large if you try
to evaluate all possible splice products of a large substrate without limits. The number of all possible
splice products of a substrate of length 100 consists of about 25 million peptides, and results into a
database of nearly 3 GB, so you can predict the size of the database without evaluating it, and avoid
the evaluation.
The ProtAG program evaluates a database of splice products in fasta format according different
parameters:
. Sequence of the substrate of length L(sub).
. Minimal/maximal length of the parts of the splice peptides (MinP,MaxP).
. Minimal/maximal length of the gap between the parts of the splice peptide (only used if you
evaluate splice peptides in normal or inverse order) (MinG,MaxG).
. Minimal/maximal length of the whole splice peptide (MinS,MaxS).
. Do you want to include PCPs into the database (recommended)?
. Do you want to exclude PSPs with sequences identical to PCPs (recommended)?
. Do you want to evaluate only PSPs in normal order, or PSPs in normal or inverse order (coming
from the same substrate), or all PSPs including PSPs from different substrates?
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Algorithm
Algorithm for the evaluation of PSPs in normal or inverse order – ignoring MaxG for
simplification:
– evaluate all possible lengths of splice products actL with MinS<=actL<=MaxS
– evaluate possible lengths for the parts: MinP<=actL1<=min(actL-MinP,MaxP), actL2=actL-
actL1
– evaluate starting points for the first fragment of the splice peptide: 1<=Start1<=L(sub)-actL-
MinG+1
endpoint for the first fragment will be End1=Start1+actL1-1
– evaluate starting points for the second fragment: End1+1+MinG<=Start2<=L(sub)-actL2+1
endpoint for the second fragment will be End2=Start2+actL2-1
– evaluate the normal PSP SP(Start1,End1,Start2,End2) if Start2 >End1+1
check if the sequence of the PSP is a sub sequence of the substrate
– if not: write out the PSP in fasta format with the name line containing information to the
positions
Start1, End1, Start2, End2, mass, m/z values for z=1,2,3
– if inverse PSPs should be included: evaluate the inverse PSP SP (Start2, End2, Start1, End1)
– check if the sequence of the PSP is a sub sequence of the substrate
if not: write out the PSP in fasta file format
The ProtAG algorithm, together with an instruction sheet is available on Dryad.
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